Markets:

Overview

News

Currencies

International

Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

27.01 +0.30 (+1.12%)

Streaming Delayed Price Updated: 1:23 PM EST, Mar 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Immunovant, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability

February 26, 2026

As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"...

Via Finterra

Immunovant (IMVT) Q2 2025 Earnings Call Transcript ↗

February 06, 2026

Immunovant (IMVT) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Via Finterra

Topics ETFs Economy Initial Public Offering

Immunovant Inc (NASDAQ:IMVT) Reports Q3 FY2026 Results, Beats EPS Estimates and Provides Key Clinical Updates ↗

February 06, 2026

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Insights into Immunovant's Upcoming Earnings ↗

November 07, 2025

Via Benzinga

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? ↗

December 18, 2025

Focused on monoclonal antibody therapies for autoimmune diseases, this biotech just reported a significant insider buy in public filings.

Via The Motley Fool

Topics Regulatory Compliance

Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates ↗

November 10, 2025

Immunovant stock drops 10% despite meeting Q2 FY2026 earnings estimates. The sell-off is driven by investor reaction to clinical pipeline updates for its anti-FcRn therapies.

Via Chartmill

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗

October 30, 2025

Via Benzinga

Four Stocks To Watch This Week - Monday, Sep. 23 ↗

September 23, 2024

For this week, we expect a slight pause in momentum, though nothing particularly dramatic.

Via Talk Markets

Why Immunovant Stock Blasted Higher Today ↗

September 03, 2025

The biotech looks as if it has a promising treatment for an autoimmune disorder.

Via The Motley Fool

Immunovant Posts 34% R&D Jump in Q1 ↗

August 11, 2025

Via The Motley Fool

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence ↗

May 29, 2025

The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share.

Via Stocktwits

Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

April 22, 2025

Via Benzinga

Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift ↗

April 21, 2025

The company is getting a new chief executive and a new chief financial officer amid sweeping changes.

Via Investor's Business Daily

Topics Government

Top 2 Health Care Stocks That May Collapse This Quarter ↗

September 09, 2024

Via Benzinga

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated ↗

April 21, 2025

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company.

Via Stocktwits

Topics Government Retirement Stocks

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data ↗

March 19, 2025

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.

Via Benzinga

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled. ↗

March 19, 2025

The companies reported positive results for their lead asset in patients with two rare diseases.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 19, 2025

Via Benzinga

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity ↗

March 04, 2025

Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.

Via Investor's Business Daily

High Frequency Trading, PPI Misreads Helped Fuel a Short Squeeze... Now What ↗

January 19, 2025

With inflation and jobs behind us, it’s time to shift our focus 6,700 miles west to Tokyo. The Bank of Japan appears poised for another rate hike next week, with odds now at 77%. Monitor the VIX for...

Via Talk Markets

Topics Economy Stocks

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗

September 25, 2024

Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.

Via Investor's Business Daily

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? ↗

September 09, 2024

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the...

Via Benzinga

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay ↗

May 30, 2024

Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday.

Via Investor's Business Daily

IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024 ↗

May 29, 2024

IMVT stock results show that Immunovant missed analyst estimates for earnings per share the fourth quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 29, 2024

Via Benzinga

Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study ↗

May 29, 2024

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

Via Benzinga

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 29, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.